Product Description
Orynotide ORTD-1 is being developed as a novel treatment for rheumatoid arthritis, COVID-19, and other systemic inflammatory diseases.
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous,Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Oryn Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: COVID-19|Pneumonia
Phase 1: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ORTD1-002 | P1 |
Completed |
Arthritis, Rheumatoid |
2021-10-12 |
70% |
2021-10-20 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| ORTD1-COV-001 | P2 |
Withdrawn |
COVID-19|Pneumonia |
2021-05-01 |
5% |
2021-06-15 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |